Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Olaparib,"breast cancer, metastatic, germline PALB2 pathogenic variant HER2-negative",Olaparib (Lynparza),Recommended for decline,Community,
